MiNK Therapeutics: Promising Clinical Trials and Strategic Plans Justify Buy Rating

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on MiNK Therapeutics (INKT – Research Report), with a price target of $35.00.

Emily Bodnar has given her Buy rating due to a combination of factors including promising clinical trial results and strategic plans for future studies. MiNK Therapeutics has reported a complete response (CR) in a testicular cancer patient treated with their agenT-797 monotherapy, which indicates potential efficacy and long-term stability without additional treatment. This outcome suggests that agenT-797 can effectively modulate the tumor microenvironment and create immunomodulatory effects.
Furthermore, the company has made significant progress in its Phase 2 gastric cancer study, with the majority of patients now enrolled and initial efficacy data expected by late 2025 or early 2026. The early translational data from this study showed promising increases in immune cell activity and proinflammatory cytokines, indicating potential therapeutic benefits. These developments, along with plans to initiate GvHD trials, contribute to the positive outlook and justify the Buy rating.